Dr Francesco Marincola
Sidra Medical and Research Center, Qatar
Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.
The journal covers all areas of translational medicine but also has several special sections:
- Cancer microenvironment - Edited by Fernando Vidal-Vanaclocha
- Cardiovascular, Metabolic and Lipoprotein Translation- Edited by Nehal N. Mehta
- Cell, tissue and gene therapy - Edited by David Stroncek
- Clinical translation - Edited by George Coukos
- Combination strategies - Edited by Paolo A. Ascierto
- Computational modeling and epidemiology- Edited by Michael Liebman and Sabrina Molinaro
- Disease biomarkers - Edited by Xiangdong Wang
- Immunobiology and immunotherapy - Edited by Adrian Bot
- Immunovirology - Edited by Luigi Buonaguro
- Medical Bioinformatics - Edited by Samir K. Brahmachari
- Neuroscience - Edited by Luis F. Alguacil
- Nutrition & metabolism - Edited by Laura Soldati
- Patient-targeted molecular therapies - Edited by Francesco Chiappelli
- Personalised medicine - Edited by Lotfi Chouchane (Qatar Foundation, Weill Cornell Medical College)
Translational Medicine, intended as a strategy to accelerate the exploitation of basic research to improve the outcome of human disease, is confronting major practical hurdles that have dramatically limited its successful application. BioMed Central has shown strong interest in fostering a journal dedicated to cover all the aspects of this complex endeavor with the ultimate goal of increasing the communication between basic and clinical scientists.
Dr. Francesco M. Marincola, MD, FACS, is the inaugural Chief Research Officer of Sidra Medical and Research Center, a unique hospital and research center in Doha, Qatar. Dr. Marincola will lead the development of Sidra’s research capabilities to create a center of excellence for research focusing on medical conditions, epidemiology and issues that primarily afflict the people of the Arab world, including diabetes, cancer and fetal-maternal health.
Dr. Marincola joined Sidra from the U.S. National Institutes of Health (NIH), where he held the positions of Chief of the Infectious Disease and Immunogenetics Section (IDIS) and Tenured Senior Investigator. He was also Director or the Immunogenetics Program, Department of Transfusion Medicine, Director of the Federation of Clinical Immunology Societies (FOCIS) Center for Excellence and Co-Director of the Trans-NIH Center for Human Immunology. He is President of the Society for the Immunotherapy of Cancer and President of the International Society for Translational Medicine.
Dr Marincola is also Adjunct Professor at Peking Union Medical College, Beijing, China; First Military Medical University, Tonghe, Guangzhou, China; Shenzhen Institute of Xiangxya Biomedicine, Shenzhen, China and Universidad del Rosario, Bogota, Colombia. In addition, Dr. Marincola served and serves on several advisory boards, currently including the National Cancer Institute (NCI), the Cancer Immunology Trial Network and the Pharma Foundation, and is on the steering committee for the worldwide cancer immunotherapy immunoscore initiative.
Dr. Marincola received his MD summa cum laude from the University of Milan and his surgery training from Stanford University. He is the author of more than 500 peer-reviewed research articles and his work has been cited more than 16,000, times with an average of 1,200 citations per year and an H index of 63. He has been invited to speak at over 300 national and international meetings. Dr. Marincola is the second most cited scientist in the field of melanoma during the last ten years, with 55 papers cited 3,704 times to date. His research interest is primarily translational and focuses on the development of strategies for the dynamic study of patients’ response to therapies. His approach has deepened understanding of the mechanisms leading to rejection of tumors, allograft, graft versus host disease and leading to the development of autoimmunity.
